Status:
WITHDRAWN
Effect of PRM-125 on Ambulatory Blood Pressure
Lead Sponsor:
PRM Pharma, LLC
Conditions:
Hypertension
Eligibility:
All Genders
30-80 years
Phase:
PHASE3
Brief Summary
Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults with Hypertension
Detailed Description
Approximately 60 subjects with primary hypertension are treated for 8 weeks with PRM125 to determine if Ambulatory Blood Pressure is changed.
Eligibility Criteria
Inclusion
- primary hypertension
Exclusion
- medical conditions that preclude evaluation and/or adversely effect subject safety
Key Trial Info
Start Date :
December 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05195827
Start Date
December 20 2021
End Date
November 30 2022
Last Update
March 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AMR
Coral Gables, Florida, United States, 33134